F
Florian Schödel
Researcher at Merck & Co.
Publications - 44
Citations - 2644
Florian Schödel is an academic researcher from Merck & Co.. The author has contributed to research in topics: Vaccination & Rubella. The author has an hindex of 22, co-authored 42 publications receiving 2164 citations. Previous affiliations of Florian Schödel include United States Military Academy.
Papers
More filters
Journal ArticleDOI
Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial
George Armah,Samba O. Sow,Robert F. Breiman,Robert F. Breiman,Michael J. Dallas,Milagritos D. Tapia,Daniel R. Feikin,Daniel R. Feikin,Fred Binka,A. Duncan Steele,Kayla F. Laserson,Kayla F. Laserson,Nana Akosua Ansah,Myron M. Levine,Kristen D.C. Lewis,Michele L. Coia,Margaret Attah-Poku,Joel Ojwando,Joel Ojwando,Stephen B. Rivers,John C. Victor,Geoffrey Nyambane,Geoffrey Nyambane,Abraham Hodgson,Florian Schödel,Max Ciarlet,Kathleen M. Neuzil +26 more
TL;DR: In infants in developing countries in Asia, pentavalentrotavirus vaccine is safe and efficacious against severe rotavirus gastroenteritis, and the results support expanded WHO recommendations to promote its global use.
Journal ArticleDOI
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.
Hana M. El Sahly,Lindsey R. Baden,Brandon Essink,Susanne Doblecki-Lewis,Judith M. Martin,Evan J. Anderson,Thomas B. Campbell,Jesse L. Clark,Lisa A. Jackson,Carl J. Fichtenbaum,Marcus J. Zervos,Bruce Rankin,Frank Eder,Gregory Feldman,Christina Kennelly,Laurie Han-Conrad,Michael Levin,Kathleen M. Neuzil,Lawrence Corey,Peter B. Gilbert,Holly Janes,Dean Follmann,Mary A. Marovich,Laura Polakowski,John R. Mascola,Julie E. Ledgerwood,Barney S. Graham,Allison August,Heather Clouting,Weiping Deng,Shu Han,Brett Leav,Deb Manzo,Rolando Pajon,Florian Schödel,Joanne E Tomassini,Honghong Zhou,Jacqueline M. Miller +37 more
TL;DR: The mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 (Covid-... as discussed by the authors ) in a phase 3, observer-blinded, placebo-controlled clinical trial.
Journal ArticleDOI
Varicella-Zoster Virus–Specific Immune Responses to Herpes Zoster in Elderly Participants in a Trial of a Clinically Effective Zoster Vaccine
Adriana Weinberg,Jane H. Zhang,Michael N. Oxman,Gary R. Johnson,Anthony R. Hayward,Michael J. Caulfield,Michael R. Irwin,James H. Clair,Jeffrey G. Smith,Harold A. Stanley,Rocio D. Marchese,Ruth Harbecke,Heather M. Williams,Ivan S. F. Chan,Robert D. Arbeit,Anne A. Gershon,Florian Schödel,Vicki A. Morrison,Carol A. Kauffman,Steve E. Straus,Kenneth E. Schmader,Larry E. Davis,Myron J. Levin +22 more
TL;DR: Higher VZV CMI at HZ onset was associated with reduced HZ severity and less postherpetic neuralgia, and higher antibody titers were associated with increased H zoster vaccine severity and occurrence of postherPetic Neuralgia.
Journal ArticleDOI
Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants.
Timo Vesikari,H Fred Clark,Paul A. Offit,Michael J. Dallas,Daniel J. DiStefano,Michelle G. Goveia,Richard L. Ward,Florian Schödel,Aino Karvonen,James E. Drummond,Mark J. DiNubile,Penny M. Heaton +11 more
TL;DR: Based on the results of this trial, a pentavalent composition (G1, G2, G3, G4, and P1A) of human-bovine (WC3) reassortant rotavirus vaccine with a potency similar to that of the middle-potencypentavalent vaccine was selected for further development.
Journal ArticleDOI
Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children
Henry R. Shinefield,Steve Black,Laura Digilio,Keith S. Reisinger,Mark M. Blatter,Jacqueline Gress,Michelle L Brown,Karen Eves,Stephanie O. Klopfer,Florian Schödel,Barbara J. Kuter +10 more
TL;DR: A 1- or 2-dose regimen of MMRV is generally well-tolerated when administered to 12- to 23-month-old children and has a safety and immunogenicity profile similar to that of M-M-R®II and VARIVAX administered concomitantly.